MediWound details results of extraordinary shareholder vote

MediWound Ltd. reported the results of an extraordinary general meeting of shareholders.

Rhea-AI Filing Summary

MediWound Ltd. reported the results of an extraordinary general meeting of shareholders. As of the January 16, 2026 record date, there were 12,815,094 ordinary shares outstanding and entitled to vote. Shareholders holding 3,844,528 ordinary shares, about 30% of the outstanding shares, were present in person or by proxy, satisfying the quorum requirements under the company’s Articles of Association and Israeli Companies Law.

The single proposal presented at the meeting was approved by the requisite majority under the Israeli Companies Law, excluding abstentions. The final vote count showed 3,490,863 votes in favor (90.9%), 350,902 votes against (9.1%), and 2,763 abstentions. The 6-K and its exhibits are incorporated by reference into MediWound’s existing Form S-8 and Form F-3 registration statements.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did MediWound Ltd. (MDWD) announce in this Form 6-K?

MediWound Ltd. announced the voting results of an extraordinary general meeting of shareholders. One proposal was presented and approved by the required majority under Israeli Companies Law, with detailed vote counts and quorum information disclosed.

How many MediWound (MDWD) shares were eligible to vote at the extraordinary meeting?

At the January 16, 2026 record date, 12,815,094 MediWound ordinary shares were outstanding and entitled to vote. This figure defines the eligible voting base for the extraordinary general meeting described in the Form 6-K.

What was shareholder turnout at MediWound’s February 2026 extraordinary meeting?

Shareholders holding 3,844,528 ordinary shares participated, representing about 30% of MediWound’s outstanding ordinary shares. This level of participation met the quorum requirements under the company’s Articles of Association and the Israeli Companies Law.

How did MediWound shareholders vote on the proposal at the extraordinary meeting?

The proposal received 3,490,863 votes in favor and 350,902 votes against, with 2,763 abstentions. This translated into 90.9% support and 9.1% opposition among votes cast, excluding abstentions, satisfying the required majority under Israeli Companies Law.

How is this MediWound Form 6-K used in existing SEC registrations?

The contents of this Form 6-K, including Exhibits 99.1 and 99.2, are incorporated by reference into MediWound’s Form S-8 and Form F-3 registration statements. This allows the disclosed meeting results to be treated as part of those registration documents.

Which MediWound SEC registration statements incorporate this 6-K by reference?

This 6-K is incorporated into MediWound’s Form S-8 registration statements filed between 2014 and 2025, and its Form F-3 registration statements filed on August 29, 2024 and March 19, 2025, using the specific registration numbers listed in the document.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/19/2026 - 04:05 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549
______________________

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16 of the
Securities Exchange Act of 1934

For the month of February 2026

Commission File Number: 001-36349

MediWound Ltd.
(Translation of registrant’s name into English)

42 Hayarkon Street

Yavne, 8122745 Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒            Form 40-F ☐

CONTENTS

Results of Extraordinary General Meeting of Shareholders

On February 19, 2026, MediWound Ltd. (“we,” “us” or the “Company”) held extraordinary general meeting of shareholders (the “Meeting”). At the Meeting, our shareholders voted on the proposal described below, which was set forth in greater detail in the Company’s Notice and Proxy Statement for the Meeting, attached as Exhibit 99.1 to the Report of Foreign Private Issuer on Form 6-K furnished to the U.S. Securities and Exchange Commission (the “SEC”) on January 15, 2026, which description is incorporated herein by reference.

As of January 16, 2026 record date for the Meeting, there were 12,815,094 ordinary shares outstanding and entitled to vote. At the Meeting, shareholders holding 3,844,528 ordinary shares, representing approximately 30% of the Company’s outstanding ordinary shares as of the record date, were present in person or by proxy, constituting a quorum in accordance with the Company’s Articles of Association and the Israeli Companies Law, 5759-1999 (the “Companies Law”).

The proposal presented at the Meeting was approved by the requisite majority under the Companies Law, with the majority determined after excluding abstentions, as required under the Companies Law. The final voting results were as follows:

(1) Approval of an increase by 300,000 in the number of ordinary shares reserved for issuance under the Company’s 2024 Share Incentive Plan

Votes in Favor			Votes Against			Abstentions
3,490,863 (90.9%)			350,902 (9.1%)			2,763

Incorporation by Reference

The contents of this Form 6-K (including the information contained in Exhibits 99.1 and 99.2) are hereby incorporated by reference into the Company’s Registration Statements on (i) Form S-8, filed with the SEC on April 28, 2014, March 24, 2016, March 19, 2018, March 25, 2019, February 25, 2020, May 15, 2021 August 9, 2022, August 15, 2023, and March 19, 2025 (Registration Nos. 333-195517, 333-210375, 333-223767, 333-230487, 333-236635, 333-255784, 333-266697, 333-273997, and 333-285897, respectively), and (ii) Form F-3, filed with the SEC on August 29, 2024 and March 19, 2025 (Registration Nos. 333-281843 and 333-285908, respectively).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: February 19, 2026 MEDIWOUND LTD.   By: /s/ Hani Luxenburg Name: Hani Luxenburg Title: Chief Financial Officer